A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional
Issue link: http://bariatrictimes.epubxp.com/i/800348
20 The Medical Student Notebook Bariatric Times • March 2017 mean BMI from 49 to 27.5kg/m 2 r eported improvement of visual field deficits in every patient. 85 The other study that reported data on visual field deficits included four patients who underwent LAGB, two o f whom had pre-operative visual field deficits. Both experienced improvement, but not full resolution, of visual field deficits postoperatively. 87 In comparison, p atients in the nonsurgical group experienced improvement of papilledema in 66.7 percent of cases, visual field deficits in 75.4 percent of cases, headache in 23.2 p ercent of cases, and an average decrease in CSF opening pressure of 61.0mmHg. Comparing these outcomes between the surgical and nonsurgical groups demonstrates s uperior efficacy of bariatric surgery in alleviating disease burden of IIH. This is in keeping with the well-established evidence that bariatric surgery leads to g reater and more sustained weight loss as well as higher remission rates of several other obesity related comorbidities than nonoperative management. 7,88 Limitations. While this systematic review suggests a prominent role for weight loss in the treatment of IIH, and specifically the potential efficacy of bariatric surgery, there are several important limitations. First, the surgical studies are relatively small and comprise a total of only 65 patients. Second, the individual studies included are generally observation rather than prospective, randomized, control trials. Third, bariatric surgery would not be an appropriate treatment in the subset of patients with IIH who do not have obesity or overweight or who are not suitable surgical candidates. Additionally, bariatric surgery is not appropriate in the subset of patients with rapidly progressive visual loss, given that it entails a lengthy pre- operative process as well as postoperative time required for significant reduction in BMI. Nevertheless, bariatric surgery remains a promising component of IIH treatment that directly intervenes on one of the presumed underlying disease processes of IIH rather than simply treating the downstream effects of these processes as do other interventions, such as nonbariatric surgical interventions like CSF shunting procedures. CONCLUSION Several authors have suggested that IIH be formally and consistently included in worldwide clinical practice guidelines for indications for bariatric surgery. 83,89 While the theoretical basis for benefit of bariatric surgery in patients with IIH is clear and the a vailable data supports the notion of significant clinical improvement following bariatric surgery, further research is necessary to answer several remaining questions, i ncluding which bariatric procedure is most beneficial for these patients as well as the most appropriate BMI and symptomatic criteria such that the expected benefits outweigh the r isks of surgery. ACKNOWLEDGEMENT The author of this article would like to thank Nurhan Torun, MD for h er invaluable assistance with reviewing this article. Dr. Torun is on staff in the Division of Ophthalmology at Beth Israel Deaconess Medical Center (BIDMC) a nd serves as Assistant Professor of Ophthalmology at Harvard Medical School, Boston, Massachusetts. REFERENCES 1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806–814. 2. Ogden CL, Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. JAMA. 2016;315(21):2292–2299. 3. Levi J, Segal LM LR, Lang A, Rayburn J: F as in Fat: How obesity threatens America's future. In: Robert Woods Johnson Foundation & Trust for America's Health Issue Report. 2012. 4. Johnson F, Cooke L, Croker H, Wardle J. Changing perceptions of weight in Great Britain: comparison of two population surveys. BMJ. 2008; 337:a494. 5. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822–w831. 6. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013; 21 Suppl 1:S1. 7. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta- analysis. Am J Med. 2009; 122:248. 8. HofsøD, Nordstrand N, Johnson LK, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163(5):735–745. 9. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–436. 10. Ashrafian H, Toma T, Rowland SP, et al. Bariatric surgery or non- surgical weight loss for obstructive sleep apnoea? A systematic review and comparison of meta-analyses. Obes Surg. 2014;1–12. 11. Bower G, Toma T, Harling L, et al. Bariatric surgery and non- alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;1–10. 12. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002;59:1492. 13. Friedman DI, McDermott MP, Kieburtz K, et al. The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol. 2014;34:107. 14. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol. 1988;45:875. 15. Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1993; 50:78. 16. Kesler A, Gadoth N. Epidemiology of idiopathic intracranial hypertension in Israel. J Neuroophthalmol. 2001; 21:12. 17. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain. 1991;114 ( Pt 1A):155. 18. Jain N, Rosner F. Idiopathic intracranial hypertension: report of seven cases. Am J Med. 1992;93:391. 19. Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case- control study. Neurology. 1991;41:239. 20. Curry WT Jr, Butler WE, Barker FG 2nd. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988-2002. Neurosurgery. 2005; 57:97. 21. Balcer LJ, Liu GT, Forman S, et al. Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology. 1999; 52:870. 22. Cinciripini GS, Donahue S, Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. Am J Ophthalmol. 1999; 127:178. 23. Scott IU, Siatkowski RM, Eneyni M, et al. Idiopathic intracranial hypertension in children and adolescents. Am J Ophthalmol. 1997;124:253. 24. Wall M, Kupersmith MJ, Kieburtz KD, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014; 71:693. 25. Sismanis A, Butts FM, Hughes GB. Objective tinnitus in benign intracranial hypertension: an update. Laryngoscope. 1990; 100:33. 26. Chari C, Rao NS. Benign intracranial hypertension--its unusual manifestations. Headache. 1991; 31:599. 27. Wall M, White WN 2nd. Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci. 1998; 39:134. 28. Greenfield DS, Wanichwecharungruang B, Liebmann JM, Ritch R. Pseudotumor cerebri appearing with unilateral papilledema after trabeculectomy. Arch Ophthalmol. 1997; 115:423. 29. Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology. 1996; 46:1226. 30. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013; 81:1159. 31. Soler D, Cox T, Bullock P, et al. Diagnosis and management of benign intracranial hypertension. Arch Dis Child. 1998; 78:89. 32. Salman MS, Kirkham FJ, MacGregor DL. Idiopathic "benign" intracranial hypertension: case series and review. J Child Neurol. 2001; 16:465. 33. Galvin JA, Van Stavern GP. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci. 2004; 223:157. 34. Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. 1982; 39:461. 35. Rowe FJ, Sarkies NJ. Visual outcome in a prospective study of idiopathic intracranial hypertension. Arch Ophthalmol. 1999; 117:1571. 36. Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1993; 50:78. 37. Bruce BB, Preechawat P, Newman NJ, et al. Racial differences in idiopathic intracranial hypertension. Neurology. 2008; 70:861. 38. Acheson JF. Idiopathic intracranial hypertension and visual function. Br Med Bull. 2006; 79-80:233. 39. Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology. 2007; 68:229. 40. Liu GT, Glaser JS, Schatz NJ. High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol. 1994; 118:88. 41. Kidron D, Pomeranz S. Malignant pseudotumor cerebri. Report of two cases. J Neurosurg. 1989; 71:443.